Europe is emerging as an attractive route to global market access for Chinese sponsors. Early consideration of EMA requirements can help avoid costly delays and improve approval success. Read the article: https://ow.ly...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Optimism returns as biotech optimise R&D
In this article, Brandon Early, SVP Project Delivery, outlines some of the key findings from the ICON biotech sector survey of over 130 decision makers in small, mid-size, large biotech and VC organisations.
-
ICON predicts biotech trial demand will grow despite economic pressures
This article from Clinical Insider outlines ICON’s view that the demand for clinical trial services will increase in 2024, in addition to providing an overview of the results of the recent ICON biotech sector survey, the findings of which suggest that biotech R&D spending is likely to increase.
-
48% of biotechs leaning on Big Pharma as current funding method: ICON survey
This article from Fierce Biotech provides an overview of findings from the ICON 2023 biotech sector survey, which shows that despite cash struggles, 60% of the survey respondents anticipate their R&D spend to rise over the next one to two years.
-
Due diligence and beyond
Dr. Sandra Eagle outlines how due diligence has evolved from a discrete standalone technical assessment, to now being an integrated part of the holistic development continuum of an asset.
-
Optimising biotech trial designs to stretch your cash runway
Brandon Early discusses how optimising trials designs at the earliest stages can help innovative biotech companies to maximise their available capital.
-
-
What Biotech and Pharma need to consider about decentralised trials
Discuss key considerations when implementing decentralised clinical trials, in addition to the success factors that lead to more patient-centric trials and increased patient recruitment, engagement and retention.
-
So what sectors had the most M&A activity?
This article shares how the medical and biotech sectors have dominated the mergers & acquisitions (M&A) landscape and mentions ICON’s acquisition of PRA Health Sciences. (registration required)
-
How CRO venture capital relationships can help biotech fundraising
This article considers how partnering with a CRO can help emerging biotechs to secure funding.
-
R&D outsourcing trends roundtable
Solomon Babani, SVP and General Partner, Biotech and Small/Mid-Size Pharma, contributes to this article on today’s R&D outsourcing trends across drug development, clinical trial services and manufacturing.
